JANX - Janux Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
2022-12-31
2021-12-31
2020-12-31
2019-12-31
Total Revenue
8,612
8,612
3,637
0
0
Operating Expenses
Research Development
53,441
53,441
26,237
3,041
2,999
Selling General and Administrative
22,262
22,262
10,329
1,802
772
Total Operating Expenses
75,703
75,703
36,566
4,843
3,771
Operating Income or Loss
-67,091
-67,091
-32,929
-4,843
-3,771
Interest Expense
-
-
0
206
233
Total Other Income/Expenses Net
-
4,032
257
-1,735
-
Income Before Tax
-63,059
-63,059
-32,672
-6,784
-4,004
Income from Continuing Operations
-63,059
-63,059
-32,672
-6,784
-4,004
Net Income
-63,059
-63,059
-32,672
-6,784
-4,004
Net Income available to common shareholders
-63,059
-63,059
-32,672
-6,784
-4,004
Basic EPS
-
-1.52
-1.39
-0.54
-0.62
Diluted EPS
-
-1.52
-1.39
-0.54
-0.62
Basic Average Shares
-
41,470
23,530
12,473
6,415
Diluted Average Shares
-
41,470
23,530
12,473
6,415
EBITDA
-
-67,091
-32,929
-6,565
-3,765